Ebola future or investigational therapies: Difference between revisions
Sergekorjian (talk | contribs) |
Sergekorjian (talk | contribs) |
||
| Line 8: | Line 8: | ||
===ZMapp=== | ===ZMapp=== | ||
ZMapp is an experimental drug composed of 3 humanized monoclonal antibodies currently being investigated for the treatment of Ebola virus disease. The component monoclonal antibodies are recombinantly manufactured in a variety of tobacco (''Nicotiana benthamiana''). It has not yet been tested in humans for safety or effectiveness. Zmapp was studied in a preclinical study involving rhesus macaques exposed to the virus. The drug was successful in rescuing 100% (21/21) of the macaques when the treatment was initiated within 5 day of the Ebola exposure. High grade fever, and significant viraemia was present in many animals before intervention. Full recovery was also observed in animals with advanced disease with elevated liver enzymes, mucosal haemorrhages and generalized petechia. ZMapp was also found to be cross-reactive with the Guinean variant of Ebola. <ref name="pmid25171469">{{cite journal| author=Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB et al.| title=Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. | journal=Nature | year= 2014 | volume= 514 | issue= 7520 | pages= 47-53 | pmid=25171469 | doi=10.1038/nature13777 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25171469 }} </ref> | ZMapp is an experimental drug composed of 3 humanized monoclonal antibodies currently being investigated for the treatment of Ebola virus disease. The component monoclonal antibodies are recombinantly manufactured in a variety of tobacco (''Nicotiana benthamiana''). It has not yet been tested in humans for safety or effectiveness. Zmapp was studied in a preclinical study involving rhesus macaques exposed to the virus. The drug was successful in rescuing 100% (21/21) of the macaques when the treatment was initiated within 5 day of the Ebola exposure. High grade fever, and significant viraemia was present in many animals before intervention. Full recovery was also observed in animals with advanced disease with elevated liver enzymes, mucosal haemorrhages and generalized petechia. ZMapp was also found to be cross-reactive with the Guinean variant of Ebola. <ref name="pmid25171469">{{cite journal| author=Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB et al.| title=Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. | journal=Nature | year= 2014 | volume= 514 | issue= 7520 | pages= 47-53 | pmid=25171469 | doi=10.1038/nature13777 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25171469 }} </ref> | ||
===AVI-6002 and AVI-6003=== | |||
==References== | ==References== | ||
Revision as of 17:44, 17 October 2014
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Ebola future or investigational therapies |
|
Risk calculators and risk factors for Ebola future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Michael Maddaleni, B.S.
Overview
Although there is no effective human vaccine against Ebola currently available, there are promising results for antisense prevention therapies targeting the Ebola virus in monkey studies. Administration of an inhibitor of coagulation (rNAPc2) has demonstrated some benefit in monkey studies. There are non-conclusive results in human survivors from post-exposure vaccination, passive immunization with blood or serum or with recombinant human monoclonal antibodies.
Investigational Therapies
ZMapp
ZMapp is an experimental drug composed of 3 humanized monoclonal antibodies currently being investigated for the treatment of Ebola virus disease. The component monoclonal antibodies are recombinantly manufactured in a variety of tobacco (Nicotiana benthamiana). It has not yet been tested in humans for safety or effectiveness. Zmapp was studied in a preclinical study involving rhesus macaques exposed to the virus. The drug was successful in rescuing 100% (21/21) of the macaques when the treatment was initiated within 5 day of the Ebola exposure. High grade fever, and significant viraemia was present in many animals before intervention. Full recovery was also observed in animals with advanced disease with elevated liver enzymes, mucosal haemorrhages and generalized petechia. ZMapp was also found to be cross-reactive with the Guinean variant of Ebola. [1]
AVI-6002 and AVI-6003
References
- ↑ Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB; et al. (2014). "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp". Nature. 514 (7520): 47–53. doi:10.1038/nature13777. PMID 25171469.